Disclaimer: This is a user generated content submitted by a member of the WriteUpCafe Community. The views and writings here reflect that of the author and not of WriteUpCafe. If you have any complaints regarding this post kindly report it to us.

Roots Analysis has done a detailed study on Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030, covering key aspects of the industry and identifying key future growth opportunities.

To order this 370+ page report, which features 190+ figures and 180+ tables, please visit this link

Key Market Insights 

  • Several novel biomarkers are presently under investigation for a variety of cancer indications; the initiatives of big pharmaceutical companies are indicative of the growing interest in this domain
  • Presently, close to 50 companies are offering a variety of analytical testing solutions for the assessment of novel cancer biomarkers; majority of these tests are intended to facilitate important therapy-related decisions
  • Multiple tests are currently available for specific diseases indications; next generation sequencing has emerged as a key driver, enabling high throughput results and faster turnaround times
  • Companies involved in this domain are putting in significant efforts to develop efficient tests and differentiate their offerings, from those of other stakeholders, to maintain a competitive edge
  • Till date, close to 200 trials, evaluating the expression of novel biomarkers have been registered across different cancer indications, phases of development and geographical locations
  • The growing research activity in this domain is also evident across published scientific literature; several biomarker-focused studies are evaluating different types of immunotherapies 
  • The growing interest in this field is also reflected by the 120+ partnerships have been signed in the last two years, involving both international and indigenous stakeholders
  • The opportunity is likely to be driven by the applicability of these tests across multiple cancer indications; the market is anticipated to grow as more biomarker based drugs get approved in the coming decade
  • The projected future opportunity is expected to be distributed across different application areas, types of analytical techniques used and various global regions

For more information, please visit https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi–mmr-and-tils-testing-2019–2030/253.html


Table of Contents


1.                     PREFACE

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines





3.1.       Chapter Overview

3.2.       Cancer Immunotherapy

3.2.1.    Cancer Immunotherapy Biomarkers

3.2.2.    Identification of a Candidate Biomarker

3.2.3.    Need for Novel Cancer Biomarkers

3.3.       Tumor Mutation Burden (TMB)

3.3.1.    Overview

3.3.2.    Variation of TMB across Multiple Indications

3.3.3.    Methods for Measurement of TMB

3.3.4.    Factors Affecting Measurement of TMB

3.3.5.    Initiatives for Assessment of TMB as a Potential Biomarker

3.4.       Microsatellite Instability / Mismatch Repair Deficiency (MSI / MMR)

3.4.1.    Overview

3.4.2.    Variation of MSI across Multiple Indications

3.4.3.    Methods of Measurement of MSI

3.5.       Tumor Infiltrating Lymphocytes and Other Novel Biomarkers


4.1.       Chapter Overview

4.2.       Cancer Biomarkers Testing Services: Overall Market Landscape

4.2.1.    Analysis by Year of Establishment

4.2.2.    Analysis by Company Size

4.2.3.    Analysis by Geographical Location

4.2.4.    Analysis by Test Availability

4.2.5.    Analysis by Type of Biomarker

4.2.6.    Analysis by Application Area

4.2.7.    Analysis by Disease Indication

4.2.8.    Analysis by Analytical Technique Used

4.2.9.    Analysis by Turnaround Time

4.2.10.  Analysis by Sample Input

4.2.11.  Analysis by Nucleic Acid Tested

4.2.12.  Key Players: Analysis by Type of Biomarker

4.3.       TMB Tests

4.3.1.    Analysis by Application Area

4.3.2.    Analysis by Disease Indication

4.3.3.    Analysis by Analytical Technique Used

4.3.4.    Analysis by Turnaround Time

4.4.       MSI / MMR Tests

4.4.1.    Analysis by Application Area

4.4.2.    Analysis by Disease Indication

4.4.3.    Analysis by Analytical Technique Used

4.4.4.    Analysis by Turnaround Time

4.5.       TIL-based Tests

4.5.1.    Analysis by Application Area

4.5.2.    Analysis by Disease Indication

4.5.3.    Analysis by Analytical Technique Used

4.5.4.    Analysis by Turnaround Time



5.1.       Chapter Overview

5.2.       Product Competitiveness Analysis: Key Assumptions and Methodology

5.2.1.    Tests for the Assessment of TMB

5.2.2.    Tests for the Assessment of MSI / MMR

5.2.3.    Tests for the Assessment of TILs


6.1.       Chapter Overview

6.2.       Dr Lal PathLabs

6.2.1.    Company Overview      

6.2.2.    Financial Information    

6.2.3.    Product / Service Portfolio Biomarkers Testing Portfolio Microsatellite Instability (MSI) by PCR OncoPro NCCN Lung Cancer Panel (*9 Genes *MSI) OncoPro Liquid Biopsy 73 Gene Panel with MSI          

6.2.4.    Recent Developments and Future Outlook         

6.3.       Foundation Medicine    

6.3.1.    Company Overview      

6.3.2.    Financial Information    

6.3.3.    Product / Service Portfolio Biomarkers Testing Portfolio FoundationOne CDx FoundationOne Liquid FoundationOne Heme

6.3.4.    Recent Developments and Future Outlook         


6.4.       NeoGenomics Laboratories       

6.4.1.    Company Overview      

6.4.2.    Financial Information    

6.4.3.    Product / Service Portfolio Biomarkers Testing Portfolio NeoTYPE Discovery Profile for Solid Tumors MSI Analysis / MMR Panel by IHC MultiOmyx Tumor Infiltrating Lymphocyte Panel          

6.4.4.    Recent Developments and Future Outlook         

6.5.       Novogene        

6.5.1.    Company Overview      

6.5.2.    Product / Service Portfolio Biomarkers Testing Portfolio NovoPM Cancer Panel    NovoPM TMB NovoPM bTMB NovoPM MSI

6.5.3.    Recent Developments and Future Outlook

6.6.       Q2 Solutions    

6.6.1.    Company Overview      

6.6.2.    Product / Service Portfolio Biomarkers Testing Portfolio TMB Assay MSI Assay TILs Testing  

6.6.3.    Recent Developments and Future Outlook


Welcome to WriteUpCafe Community

Join our community to engage with fellow bloggers and increase the visibility of your blog.
Join WriteUpCafe